[ Back to EurekAlert! ] Public release date: 1-May-2013
[ | E-mail Share Share ]

Contact: Molly Wilson
molly.wilson@toniclc.com
215-490-3009
Tonic Life Communications USA

Ferring to present safety analysis for FIRMAGON® (degarelix) at the AUA Annual Meeting

San Diego, CA, USA, May 1, 2013 – The following data will be presented at the annual meeting of the American Urology Association (AUA) in San Diego, CA:

Per AUA media embargo policy, coverage of research being presented is prohibited before the date and time of presentation.

###

About Ferring

Headquartered in Switzerland, Ferring Pharmaceuticals is a research-driven, specialty biopharmaceutical group active in global markets. The company identifies, develops and markets innovative products in the areas of reproductive health, urology, gastroenterology and endocrinology. Ferring has its own operating subsidiaries in 50 countries and markets its products in more than 90 countries. To learn more about Ferring or its products, please visit http://www.ferring.com.

For More Information:

Molly Wilson
Tonic Life Communications
Tel: (215) 928-2357
molly.wilson@toniclc.com

Patrick Gorman
Ferring Pharmaceuticals
Tel: +41 (0) 58 301 00 53
patrick.gorman@ferring.com
© 2013 Ferring B.V.
FIRMAGON® is a registered trademark of Ferring B.V.



[ Back to EurekAlert! ] [ | E-mail Share Share ]

 


AAAS and EurekAlert! are not responsible for the accuracy of news releases posted to EurekAlert! by contributing institutions or for the use of any information through the EurekAlert! system.